会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明专利
    • Improvements in and relating to the preparation of derivatives of cholesterol
    • GB614193A
    • 1948-12-10
    • GB2017646
    • 1946-07-05
    • GLAXO LAB LTDAUSTIN ERNEST BIDEPETER ALFRED WILKINSON
    • C07J9/00C07J75/00
    • 7-Halogenocholesteryl halides are obtained by treating cholesteryl chloride or bromide in a suitable solvent with a halogenating agent, e.g. N-bromosuccimide, N-bromophthalimide, unsubstituted N-chloro- or bromo-amides of fatty acids having not more than 6 carbon atoms in the molecule, N-chloro- or bromo-acetanilides, having on the para position and, if desired, on either or both of the ortho positions of the benzene ring, groupings such as will prevent the migration of the N-halogen into the para and/or ortho position, these substituents being of such a nature as to be inert to the reagents or products in the reaction mixture, substances having the formula R.CO.NH.X, where X is chlorine or bromine and R is phenyl or substituted phenyl, excluding such substituents as would react under the conditions of the reaction either with the halogenating agent or with the halogenated steroid. Suitable solvents are those which under reaction conditions are inert both to the reaction components and products, e.g. petrol b.p. about 80 DEG C. Preferably, the reaction is brought about by heating to the b.p. of the solvent. The 7-halogencholesteryl halide may with or without isolation be dehydrohalogenated by methods described in Specification 574,432. Detailed examples are given of methods using N-bromosuccinimide as a halogenating agent.
    • 4. 发明专利
    • Improvements in and relating to the purification of penicillin salts
    • GB604563A
    • 1948-07-06
    • GB3203245
    • 1945-11-27
    • GLAXO LAB LTDAUSTIN ERNEST BIDEWILLIAM GRAHAMERNEST LESTER SMITHPETER ALFRED WILKINSON
    • C07D499/00C07D499/26
    • Salts of penicillin of a high degree of purity are prepared by dissolving a crude metallic (preferably sodium or calcium) salt of penicillin (preferably of not less than 20 per cent purity) in water (preferably in such quantity as to give a concentration of about 1 per cent w/v.), acidifying (preferably to about pH 2.5) with a strong acid, and combining the liberated penicillin acid with one or more tertiary organic bases selected from N-alkylated piperidines, with or without one or more methyl groups as substituents on the carbon atoms of the ring, or N-alkylated pyrrolidines, with or without one or more methyl or ethyl groups (or both) as substituents on the carbon atoms of the ring, the total number of exocyclic carbon atoms in either case not exceeding 5. Preferably, the free penicillin is extracted, before combination with the base, into a suitable solvent (i.e. one into which penicillin can be extracted readily from acidified aqueous solution and which is relatively inert to penicillin, and in which the tertiary base salts of penicillin are relatively insoluble), preferably so as to give a concentration of penicillin therein of 0.25-5 per cent w/v, and advantageously after adding to the aqueous solution a highly soluble neutral inorganic salt commonly used for salting out purposes, and there is added to the extract a suitable secondary solvent (capable of retaining the tertiary base salts of the impurities in solution). As an alternative or in addition to adding the secondary solvent, the precipitate subsequently produced by the addition of at least (and usually considerably more than) one molar equivalent of the tertiary base or bases is washed with (or crystallized from) the secondary solvent or a mixture thereof with the first solvent, and may, if desired, be further purified by recrystallization from an organic solvent or mixture of solvents. To obtain a metal salt of penicillin of a similar high degree of purity, an aqueous solution of the tertiary base salt is treated with a mineral acid, the liberated penicillin is extracted into an organic solvent, and there is added to the extract an aqueous solution or suspension of a metallic hydroxide. In examples: (1) crude penicillin sodium or calcium salt is dissolved in ice-cold water with the addition of sodium chloride followed by ether and then by dilute phosphoric acid, the ether layer is separated the residue extracted with more ether, the combined ethered extracts filtered at -80 DEG C. and shaken with charcoal which is separated by filtration and eluted with ether, then acetone is added to the eluate, followed by a solution of N-ethyl-piperidine in ether, the precipitated salt is filtered off, washed with acetone, dried, and recrystallized if desired by dissolving in warm methylene chloride, adding acetone and then slowly adding carbon tetrachloride; the product may be converted into the pure sodium salt by dissolving it in ice-cold water, shaking with chloroform while adding dilute phosphoric acid, again extracting the aqueous layer with chloroform, neutralizing the combined extracts with aqueous sodium hydroxide, freeze-drying and crystallizing from acetone; (2) the ethereal solution obtained as in (1) is treated with N-n-propylpiperidine, either with the preliminary addition of acetone or with recrystallization of the precipitated salt therefrom; (3) crude penicillin calcium salt is treated as in (1) but using methyl isobutyl ketone instead of ether; (4) crude penicillin calcium salt is treated as in (1) but using methyl ethyl ketone as the secondary solvent and N-ethylhexahydro-a -picoline as the base; (5) the N-ethylpiperidine in (1) is replaced by N-ethylpyrrolidine. Amyl acetate is additionally specified as a suitable first solvent, and sodium nitrate, sodium sulphate, ammonium sulphate, magnesium sulphate and potassium chloride as salting out agents.
    • 5. 发明专利
    • Improvements in and relating to the preparation of derivatives of cholesterol
    • GB614194A
    • 1948-12-10
    • GB2017746
    • 1946-07-05
    • GLAXO LAB LTDAUSTIN ERNEST BIDEPETER ALFRED WILKINSON
    • C07J9/00C07J75/00
    • 7-Halogenocholesteryl ethers are obtained by treating cholesterol etherified in the 3-position in a suitable solvent with a halogenating agent, e.g. N-bromosuccinimide, N-bromophthalimide, unsubstituted N-chloro- or bromo-amides of fatty acids, having not more than six carbon atoms in the molecule, N-chloro- or bromoacetanilides, having on the para p position and, if desired, on either or both of the ortho positions of the benzene ring, groupings such as will prevent the migration of the N-halogen into the para and/or ortho position, these substituents being of such a nature as to be inert to the reagents or products in the reaction mixture, substances having the formula R.CO.NH.X, where X is bromine or chlorine and R is phenyl or substituted phenyl, excluding such substituents as would react under the conditions of the reaction either with the halogenating agent or with the halogenated steroid. Suitable solvents are those which under reaction conditions are inert both to the reaction components and products, e.g. petrol b.p. about 80 DEG C. Preferably, the reaction is brought about by heating to the b.p. of the solvent. The 7-halogen cholesteryl ether may, with or without isolation, be dehydrohalogenated by methods described in Specification 574,432. Detailed examples are given of methods using N - bromosuccimide as a halogenating agent.
    • 6. 发明专利
    • Improvements in or relating to the manufacture of substituted sulphonamido compounds
    • GB595177A
    • 1947-11-28
    • GB1171543
    • 1943-07-19
    • GLAXO LAB LTDAUSTIN ERNEST BIDEHERBERT WILLIAM GODDARDPETER ALFRED WILKINSON
    • C07C311/37
    • Substituted sulphonamido compounds of therapeutic interest are formed by heating a benzenesulphonamide of the general formula or an alkali metal derivative thereof, with a compound, other than guanidine, of the type (X representing a chlorine or bromine atom, or an amino, or mono-acyl amino group; Y representing an alkyl, aryl or aralkyl radical, or an amino group; and R representing a hydrogen atom or alkyl, aryl or aralkyl radical), which may be generated in situ in the reaction-mixture by decomposing a salt thereof, e.g. the carbonate or sulphate, at a temperature generally within the approximate range 110 DEG to 200 DEG C., so as to eliminate a compound of the formula R.NH2. The process may be effected in the presence of a solvent or diluent, e.g. ethylene glycol, of boiling-point not less than the temperature of reaction. The reaction yields a compound of the general formula with elimination of the compound R.NH2, or may produce this derivative together with a compound of the general formula each of these types existing in their corresponding tautomeric forms. Numerous examples are given. Ethylguanidine sulphate is prepared by refluxing methyl iso-thiourea sulphate, water and alcoholic ethylamine solution. o-4-Xylylguanidine sulphate is prepared by heating a well-ground mixture of o-4-xylidine and methyl iso-thiourea sulphate, triturating the cooled melt with 95 per cent ethyl alcohol and standing for 10-12 hours. o-4-Xylylguanidine carbonate is prepared by treating with sodium hydroxide solution an aqueous solution of crude o-4-xylylguanidine sulphate and extracting with chloroform. Nonamidine hydrochloride is prepared by treating a mixture of nononitrile and dry ethyl alcohol with dry hydrogen chloride and then refrigerating for 3 days to crystallise noniminoethyl-ether hydrochloride; dry ethyl alcohol is stirred in, followed by dry alcoholic ammonia solution and the mixture maintained at 30-40 DEG C. for 36 hours, prior to evaporating the filtrate to dryness and recrystallizing the residue. n-Octylguanidine sulphate is prepared by refluxing together methyl iso-thiourea sulphate, n-octylamine, water and ethyl alcohol until methyl mercaptan is no longer evolved.